MMT has received IRB approval for the PCD=OO ALZ clinical study to evaluate the effectiveness of several particular medications / treatments in the preventative treatment of Pre-clinical Alzheimer’s disease (ALZ). These medications are approved by FDA for other indications and have shown promise in preventing the progression of Preclinical Alzheimer’s disease and / or of Alzheimer’s disease.Typical Warning signs of Dementia
The PCD=OO ALZ clinical study will attempt to verify two recent and very critical concepts in ALZ Clinical Research.
1. Identification of individuals who are cognitively normal but who are at high risk of developing ALZ in a 24-36 month period. MMT uses a combination of standard psychometric examinations to confirm the presence of both a normal cognitive state and the apo-e gene, before proceeding to the next steps. Individuals can use a number of online resources such as the SAGE Test to self-screen for cognitive impairment, or they can request their treating / primary care doctor PMD to perform the SAGE, MMSE or similar test. Their PMD physicians can arrange for apo e testing, which can be a simple in-office blood test.
The clinical study follows this general outline :
or their PMD can contact MMT NeuroTech by email firstname.lastname@example.org for consideration of enrollment in this study. Neurologists, psychologists, Alzheimer treatment centers and other professionals interested in participating in this protocol are invited to contact MMT NeuroTech.by email email@example.com
2. In an individual who fits the above Definition of High Risk for pre-ALZ (insert or link to the popup), specific neuroimaging may be performed to confirm the presence of patterns that are highly correlated with the future development of Alzheimer’s within 18 to 24 months. The neuroimaging can be ordered thru your PMD. All cognitive and neuroimaging testing are also available as a separate service independent of the protocol. Please contact MMT NeuroTech by email firstname.lastname@example.org if interested.
3. Initiation of specific treatments thru your PMD which are designed to prevent the progression to clinical ALZ of high-risk but cognitively normal individuals.
4. Observation and testing with cognitive metrics and neuroimaging over a three year period to document the reduced rate of progression to ALZ disease in the treatment group.
5. Study participants will remain under the care of their PMD, and all testing and treatments will take place thru them.
6. Potential benefits for participation in this clinical study: